Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.

 

Stock Quote

Aug 3, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.

Press Releases

31 Juli 2020

Pfizer und BioNTech geben Liefervereinbarung mit Japan über 120 Millionen Dosen..

31 Juli 2020

BioNTech gibt Kollaboration mit Regeneron zur Entwicklung einer Melanom-Kombina..

30 Juli 2020

BioNTech veröffentlicht Daten aus Studie mit mRNA-basiertem FixVac-Melanom-Prog..